A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

NCT01638715 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

115

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Remicade
DRUG: Orencia
DRUG: Ro-Actemra
DRUG: Mabthera

Sponsor

Medical University of Vienna